Plain-English translation of NCT04756076 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Researchers are investigating whether toxic heavy metals like arsenic and lead—as well as imbalances in essential minerals like zinc and iron—play a role in causing or worsening pulmonary hypertension, a condition where blood vessels in the lungs become stiff and narrow. The study will measure 31 different metals in blood and urine samples from patients with this condition and compare them to healthy volunteers.
While scientists know that heavy metal exposure is linked to heart and blood vessel disease, very few studies have looked at whether these metals specifically contribute to lung blood vessel disease. This research aims to fill that gap by understanding how metals might damage the lungs and heart in patients with this serious condition.
You likely qualify if…
You likely don't qualify if…
You will visit the clinic at least every 6 months for your regular pulmonary hypertension care. At each visit, researchers will collect blood and urine samples to measure metal levels. The study will track your health and metal measurements over 12 months to see if there are any connections between metal exposure and how your condition develops or changes.
AI-generated summary from trial data · Jun 19, 2026 · Not medical advice
United States
Enrollment target
~110 participants
Started
December 2020
Primary completion
December 2028
Age range
18 Years and older
Last updated on clinicaltrials.gov in May 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Jiapeng Huang, MD, PhD
Jiapeng Huang
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.